The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
Whole grains and possibly cereal fiber, bran appear linked to lower risk for hepatocellular carcinoma.
[OncoTargets and Therapy] This meta-analysis evaluates prognostic factors of OS and RFS in patients treated with radiofrequency ablation.
An analysis of results from the NHS and the HPFS showed that regular use of aspirin — standard-dose 325-mg tablets — reduced hepacellular carcinoma in a dose-dependent manner.